Baseline Pro-Inflammatory Cytokine Levels Moderate Psychological Inflexibility in Behavioral Treatment for Chronic Pain

Bianka Karshikoff 1,2,*, Jenny Åström 2,3, Linda Holmström 2,3, Mats Lekander 2,4, Mike K. Kemani 3,4 and Rikard K. Wicksell 2,5

1 Department of Social Studies, University of Stavanger, 4021 Stavanger, Norway
2 Department of Clinical Neuroscience, Karolinska Institutet, 171 77 Stockholm, Sweden; jenny.astrom@ki.se (J.Å.); linda.holmstrom@ki.se (L.H.); mats.lekander@ki.se (M.L.); rikard.wicksell@ki.se (R.K.W.)
3 Medical Unit Medical Psychology, Theme Women’s Health and Allied Health Professionals, Karolinska University Hospital, 171 76 Stockholm, Sweden; mike.kemani@regionstockholm.se
4 Stress Research Institute, Department of Psychology, Stockholm University, 106 91 Stockholm, Sweden
5 Pain Clinic, Capio St. Görans Hospital, 112 19 Stockholm, Sweden
* Correspondence: bianka.karshikoff@uis.no

Abstract: Background: The medical and scientific communities struggle to understand chronic pain and find effective treatments. Multimodal approaches are encouraging but show significant individual differences. Methods: Seventy-eight persons (56 women) with chronic pain received Acceptance and Commitment Therapy and provided blood samples before and after treatment. The participants completed surveys with the blood sampling. Blood plasma was analyzed for IL-6 and TNF-α levels with the Olink Inflammation Panel (Olink Bioscience Uppsala, Sweden). The treatment effects and moderating effects of low-grade inflammation on changes in outcomes were analyzed using linear mixed models. Results: Pain interference (p < 0.001) and psychological inflexibility (p < 0.001) improved significantly during treatment, but pain intensity did not (p = 0.078). Cytokine levels did not change over the course of the treatment (IL-6/TNF-α p = 0.086/0.672). Mean baseline levels of IL-6 and TNF-α moderated improvement in psychological inflexibility during the course of treatment (p = 0.044), but cytokine levels did not moderate changes in pain interference (p = 0.205) or pain intensity (p = 0.536). Conclusions: Higher baseline inflammation levels were related to less improvement in psychological inflexibility. Low-grade inflammation may be one factor underlying the variability in behavioral treatment in chronic pain.

Keywords: psychological inflexibility; pain interference; cytokine; inflammation; chronic pain; ACT

1. Introduction

Chronic pain is common, with studies showing prevalence rates of about one in five adults suffering from chronic pain [1]. In addition to a significant impact on emotional well-being and everyday functioning for the many affected, chronic pain is related to substantial societal costs [1,2]. The medical and scientific communities are still struggling to understand the mechanisms underlying the onset and perpetuation of symptoms and find effective treatment strategies. A number of classifications and diagnoses exist, and individual differences in symptom severity and disability are significant even within a specific pain diagnosis [2–4], adding to the complexity of the condition. However, some commonalities are seen across chronic pain diagnoses, such as a considerable overlap between chronic pain and psychological suffering [1,2,4]. Increased peripheral and central inflammatory activity has also been demonstrated across a wide range of pain diagnoses [5], such as fibromyalgia [6], neuropathic pain [7] and low back pain [8]. Modern pain treatment acknowledges the complexity of chronic pain disorders and attempts to ease patient...
suffering with multimodal and individualized approaches. There is a broad consensus on the utility of behavioral interventions to alleviate symptoms and improve health and functioning [9]. However, it is also well known that individuals vary in their response to treatment [9], which calls for a better understanding of the factors influencing treatment outcomes to guide the development of customized interventions with better effects [10].

In the present study, the participants underwent Acceptance and Commitment Therapy (ACT). This exposure-oriented behavioral intervention utilizes acceptance and values-based behavioral strategies to promote the ability to engage in valued activities despite the presence of pain and distress [11,12]. This ability is called psychological (or behavioral) flexibility [13]. Psychological inflexibility, as assessed with, e.g., Psychological Inflexibility in Pain Scale (PIPS) [14], is thus a central treatment target in ACT. Psychological inflexibility is characterized by rigid behavioral repertoires aimed at avoiding pain and related distress [14,15], which may work well in the short term, but over time result in a gradual decrease in functioning without any corresponding alleviation of pain or distress [16]. This type of avoidance was recently shown to predict pain disability and depressive symptoms three years later [17]. ACT does not primarily target pain intensity or related symptoms, but rather the influence of pain on a person’s daily life [11], as assessed by, e.g., The Pain Interference Index (PII) [18]. Previous studies have shown that psychological inflexibility is a more important mediator of changes in pain interference during ACT than, e.g., pain intensity [12]. Thus, by improving the ability to effectively manage pain and related distress (i.e., decrease psychological inflexibility), ACT aims to reduce avoidance strategies and facilitate a broader and more flexible behavioral repertoire in line with personal values and long-term goals (i.e., decrease pain interference). Today, ACT has strong empirical support to improve functioning for persons with chronic pain [19]. However, more studies are needed that investigate for whom, how and under what circumstances these treatment approaches work, i.e., factors that moderate treatment outcome [10]. We propose that ongoing low-grade inflammation may be one such factor.

Experimentally induced inflammation in healthy humans and rodents increases pain sensitivity, decreases mood and changes motivational behaviors, see, e.g., [20–23] for an overview. Inflammatory activity has been established as a factor in clinically depressed patients [24] and has recently been highlighted as relevant in the perspective of predicting or moderating treatment outcomes in chronic pain [25] and depression [26]. For depression, low-grade inflammatory activity seems to be related to the failure of responding to pharmacological antidepressant treatments specifically [27,28]. Few studies have explored the role of inflammation in behavioral interventions for complex diseases, such as depression and pain. Moreover, only two studies have, to our knowledge, examined the predictive ability of low-grade inflammation on treatment success in chronic pain patients undergoing behavioral interventions. The present study follows a previous trial in which a group of chronic pain patients (n = 41) underwent behavioral treatment (ACT or applied relaxation). Results showed that baseline peripheral low-grade inflammation, operationalized as a combination of interleukin (IL)-6 and tumor necrosis factor (TNF)-α levels in the blood, moderated improvements in pain intensity and psychological inflexibility. Higher baseline inflammatory activity predicted a less favorable treatment outcome [25]. In a recent study in which persons with fibromyalgia participated in treatment comprising mindfulness-based stress reduction (MBSR), a higher ratio of pro- vs. anti-inflammatory cytokines (IL-6/IL-10) was associated with less improvement in psychological inflexibility during treatment [29]. In our study [25], we also saw a small decrease in inflammatory cytokine levels after treatment, which aligns with a meta-analysis on the effects of behavioral therapy on CRP blood levels [30]. In sum, studies evaluating inflammation as a factor influencing the outcome of behavioral treatment for chronic pain are scarce but suggest that inflammation may interfere with improvement. However, results from existing studies are not entirely congruent, and confirmative studies are needed.

Based on our previous study [25], we hypothesized that (1) pain interference and psychological inflexibility would improve following treatment, and pain intensity decrease;
(2) levels of low-grade inflammation would decrease during treatment; and (3) baseline inflammatory levels would moderate the effect of treatment on pain interference, pain intensity and psychological inflexibility.

2. Materials and Methods

2.1. Study Participants and Procedure

Study participants were recruited between 2016–2018 either consecutively via referrals to the Behavioral Pain Medicine Treatment Services at the Karolinska University Hospital or via recruitment advertising. Inclusion criteria comprised the following: ≥18 years of age; pain duration > 6 consecutive months, which did not respond to other treatments and greatly impeded everyday life; stable medication in the last two months; able to communicate in Swedish. Patients were excluded if they participated in a concurrent treatment based on cognitive behavioral therapy (CBT) or presented with severe psychiatric comorbidity that required immediate assessment and/or treatment (e.g., suicidal ideation, psychotic symptoms), or if a spontaneous improvement could be expected. Additional exclusion criteria for phlebotomy were pregnancy, breastfeeding or having given birth within the last year, and hemophilia.

Participants in the face-to-face treatment were assessed using semi-structured interviews at their first visit to the clinic by a pain physician and a psychologist. Patients receiving treatment via the internet were assessed via telephone interview by either a psychologist or candidate psychology student under supervision. When it was unclear if the pain was sufficiently evaluated to participate in the study, a physician was consulted. Psychiatric comorbidity was assessed using the Mini International Neuropsychiatric Interview, version 5 (MINI; Sheehan et al., 1998).

All participants included in the statistical analyses presented in the current paper received ACT. The treatment protocol for face-to-face treatment was delivered weekly during a three-month period [19], and the internet-delivered treatment had learning interactions every weekday for ten weeks [31]. Based on clinical logistics, treatment was made available face-to-face or via the internet. Therapy was provided by psychologists trained in CBT/ACT. When the consent form for study participation was signed, the login information for a first block of questionnaires was sent out. At the commencement of the treatment, the patient was booked for a blood sample, and the second block of questionnaires was activated. At the end of treatment, the second blood sampling was booked with the patient, and the web-based questionnaires were activated. Participants completed the self-reported questionnaires and underwent blood sampling at two time points, i.e., directly prior to treatment onset and directly following the end of treatment. Blood sampling was done in the morning, and questionnaires were filled out in conjunction with blood sampling for most patients (see details below). The study was approved by the Regional Ethical Review Board in Stockholm, Sweden (Permit Number: 2016/1252-31/2), and all participants provided informed consent.

2.2. Self-Reported Items and Questionnaires

2.2.1. Pain Interference

To assess pain interference, we used the Pain Interference Index (PII), a brief questionnaire that measures the degree to which chronic pain interferes with everyday functioning in central life domains. The PII utilizes a two-week recall period and comprises six items that are rated from 0 (‘Not at all’) to 6 (‘Completely’) using a numerical rating scale, yielding a maximum total score of 36 points. The patient is asked to what degree pain has (1) made it difficult to study/work; (2) made it difficult to do leisure activities; (3) made it difficult to spend time with friends; (4) affected mood; (5) affected the ability to do physical activities; and (6) affected sleep. The psychometric evaluation of the instrument [18] supported a single factor structure and showed satisfactory internal consistency, indicated by a Cronbach’s alpha of 0.85. Furthermore, results from this study also showed that PII
explained a significant amount of variance in pain disability, health-related quality of life and depressive symptoms, indicating adequate concurrent criterion validity.

2.2.2. Pain Intensity

Maximum pain intensity in the last two weeks was assessed by a numeric rating scale from 0 (‘No pain’) to 10 (‘Worst imaginable pain’).

2.2.3. Psychological Inflexibility

The Psychological Inflexibility in Pain Scale (PIPS) comprises 12 items, with subscales for ‘Avoidance’ (8 items) and ‘Fusion’ (4 items). Items are rated on a 7-point Likert-scale ranging from 1 (‘Never true’) to 7 (‘Always true’), with higher scores indicating greater psychological inflexibility. In terms of reliability, previous studies have shown Cronbach’s alphas of 0.89 [32] and 0.87 [14], illustrating that the questionnaire has adequate internal consistency. Regarding construct validity, the psychometric evaluations also showed that the PIPS subscales were significantly correlated ($p < 0.001$) with both subscales of the Chronic Pain Acceptance Questionnaire (CPAQ) as well as the activity avoidance subscale of the Tampa Scale of Kinesiophobia (TSK). Finally, PIPS accounted for a significant amount of variance in pain, medication use, work absence, life satisfaction, pain disability, anxiety, depression, kinesiophobia and acceptance [14], indicating adequate concurrent criteria validity.

2.2.4. Anxiety and Depressive Symptoms

To assess symptoms of anxiety and depression, we used the Generalized Anxiety Disorder 7-item scale (GAD-7) and the Patient Health Questionnaire-9 (PHQ-9), respectively. The GAD-7 is a seven-item scale that aims to assess generalized anxiety. Items are scored from 0 (‘Not at all’) to 3 (‘Nearly every day’) and summarized [33]. The PHQ-9 is a nine-item questionnaire that aims to assess the presence of depression and levels of depression over the past two weeks, and questions are scored from 0 to 3 and summarized [34].

2.3. Cytokine Analyses

Blood was collected in the morning between 8–12 a.m. (non-fasting samples) and processed within two hours. Blood samples were collected just before the treatment period and immediately after the treatment period; max. 50 mL of blood was drawn on both occasions. At elevated CRP values (>10 mg/L), the patients were informed of the results by a physician. Blood plasma was analyzed for IL-6 and TNF-α levels with Proximity Extension Assay (PEA) technology using the Olink Inflammation Panel (Olink Bioscience Uppsala, Sweden) according to the manufacturer’s instructions (for information on all cytokines in the panel, see https://www.olink.com/products/inflammation/ (accessed on 9 March 2022)). Data are expressed as normalized protein expression (NPX), which can be used for multivariate statistical analysis and express relative quantification between samples but are not an absolute quantification. For cytokines, the log-transformed values are used to improve normal distribution. A composite score based on the mean values of IL-6 and TNF-α levels at baseline were used as a measure of ongoing low-grade systemic inflammation, similar to Lasselin et al. [25].

2.4. Statistical Analyses

Treatment effects and the moderating effect of low-grade inflammation on changes in outcomes were analyzed using Linear Mixed Models (LMM). In line with the intention to treat, principle maximum likelihood estimation, an approach that uses information from all available observations, was used to estimate parameters and provides unbiased estimates and standard errors in the presence of incomplete data [35], under the assumption that data are missing at random (MAR). Random effects and their associated covariances were retained based on their model contribution, as determined by model comparisons of Akaike’s Information Criterion (AIC; [36]). The assumptions regarding the normal
distribution of residuals and homogeneity of variance were assessed, based on visual evaluation of a histogram of model residuals and by a plot of the residuals of the model against the model predicted values, respectively. Moderation, here defined as the effect of a third variable (M) on a relationship between an independent variable (X) and a dependent variable (Y), in such a manner that the relationship between X and Y changes according to the value of M, the moderator variable. In model-building terms, this translated to including an interaction term (X*M), while controlling for M and X in the model.

Models evaluating treatment effects included age, gender (demographic variables) and Body Mass Index (BMI; clinical background variable) as time-invariant control variables. When evaluating the moderating effect of baseline inflammation (M) on the relationship between time (X) and outcomes (Y), we adjusted for the influence of demographic (gender and age) and clinical background variables (BMI, medication, depression, general anxiety, maximum pain intensity and combined mean levels of IL-6 and TNF-α). Gender, age, BMI and levels of inflammation were included as time-invariant covariates, and maximum pain intensity, depression and general anxiety were included as time-varying covariates. For comparability, control variables were consistent with Lasselin et al. [25]. Lastly, we included the interaction between time (i.e., the treatment effect on the specific outcome variable across assessments) and the combined mean baseline levels of IL-6 and TNF-α. As the analyses were hypothesis-based analyses based on a prior pilot study, we did not correct for multiple comparisons. Descriptive analyses of patient characteristics and self-ratings of the included variables were performed using adequate central values and measures of dispersion. The descriptive statistics in the text and Tables 1, 2 and S1 were analyzed using R version 4.1.2 [37] and the Tableone package [38]. Statistics in Tables 3 and 4 and Figure 1 were analyzed using IBM SPSS version 26 (IBM Corp. Released 2019. Armonk, NY, USA: IBM Corp).

Table 1. Demographic and clinical background variables for the included participants.

| Variables                  | Means/Frequencies | SD/Range | N  |
|----------------------------|-------------------|----------|----|
| Age                        | 51.91             | 14.99    | 78 |
| BMI                        | 25.40             | 4.55     | 78 |
| Pain duration (years)      | 16.08             | 13.37    | 77 |
| Medicine in past two weeks | 76 (97.44%)       |          | 78 |

Table 2. Means and standard deviations for the included variables at pre- and post-assessment.

| Variables                  | Pre- Treatment | Post-Treatment | N Pre | N Post |
|----------------------------| ------------- |--------------- |------ |------ |
| Pain interference (PII)     | 20.21         | 15.27         | 78   | 59   |
| Pain intensity (max pain)   | 7.50          | 6.76          | 78   | 59   |
| Psychological inflexibility (PIPS) | 51.36       | 42.76         | 78   | 59   |
| Anxiety (GAD-7)             | 6.10          | 4.88          | 73   | 58   |
| Depression (PHQ-9)          | 9.07          | 6.93          | 73   | 58   |
| IL-6                       | 2.57          | 2.62          | 78   | 51   |
| TNF-α                      | 2.73          | 2.72          | 78   | 51   |
Table 3. Estimates of fixed effects in the model evaluating the treatment-related effect (time) on pain interference, pain intensity, psychological inflexibility and the two measured cytokines.

| Dependent Variable | Parameter | \( \beta \) | Std. Error | df | \( p \) | 95% Confidence Interval |
|--------------------|-----------|-------------|------------|----|------|------------------------|
|                    |           |             |            |    |      | Lower Bound | Upper Bound |
| Pain intensity      | Intercept | 23.678      | 3.891      | 72.452 | 0.000 | 15.923 | 31.433 |
|                    | Age       | -0.106      | 0.069      | 70.778 | 0.128 | -0.244 | 0.031 |
|                    | Gender    | -0.105      | 2.158      | 70.755 | 0.961 | -4.409 | 4.200 |
|                    | BMI       | 0.072       | 0.062      | 60.629 | 0.249 | -0.052 | 0.136 |
|                    | Time      | -4.729      | 1.258      | 51.268 | 0.000 | -7.253 | -2.205 |
|                    | Age       | -0.006      | 0.015      | 72.466 | 0.674 | -0.036 | 0.023 |
|                    | Gender    | 0.912       | 0.460      | 71.332 | 0.051 | -0.005 | 1.830 |
|                    | BMI       | 0.015       | 0.013      | 64.723 | 0.274 | -0.012 | 0.042 |
|                    | Time      | -0.419      | 0.223      | 51.486 | 0.078 | -0.887 | 0.049 |
| PIPS               | Intercept | 63.528      | 5.711      | 72.444 | 0.000 | 52.144 | 74.911 |
|                    | Age       | -0.203      | 0.101      | 70.687 | 0.049 | -0.405 | -0.001 |
|                    | Gender    | -3.623      | 3.167      | 70.671 | 0.257 | -9.939 | 2.693 |
|                    | BMI       | 0.005       | 0.091      | 60.169 | 0.952 | -0.176 | 0.187 |
|                    | Time      | -7.166      | 1.887      | 51.975 | 0.000 | -10.953 | -3.380 |
| IL-6               | Intercept | 1.033       | 0.140      | 71.366 | 0.000 | 0.754 | 1.312 |
|                    | Age       | -0.002      | 0.002      | 71.491 | 0.450 | -0.007 | 0.003 |
|                    | Gender    | -0.018      | 0.078      | 70.112 | 0.817 | -0.174 | 0.138 |
|                    | BMI       | -0.002      | 0.002      | 66.104 | 0.422 | -0.007 | 0.003 |
|                    | Time      | 0.043       | 0.030      | 45.187 | 0.160 | -0.018 | 0.104 |
| TNF-\( \alpha \)   | Intercept | 0.959       | 0.135      | 73.237 | 0.000 | 0.690 | 1.229 |
|                    | Age       | -0.001      | 0.002      | 73.293 | 0.646 | -0.006 | 0.004 |
|                    | Gender    | 0.061       | 0.076      | 72.909 | 0.426 | -0.090 | 0.212 |
|                    | BMI       | 0.000       | 0.002      | 71.764 | 0.974 | -0.004 | 0.005 |
|                    | Time      | 0.003       | 0.015      | 43.533 | 0.840 | -0.028 | 0.034 |

Dependent variables: PII (Pain interference Index); IL-6 (Interleukin 6); TNF-\( \alpha \) (Tumor Necrosis Factor alpha); PIPS (Psychological Inflexibility in Pain Scale). Cytokine values are log-transformed.

Table 4. Estimates of fixed effects in the model evaluating the moderating effect of low-grade inflammation on pain interference, pain intensity and psychological inflexibility.

| Dependent Variable | Parameter | \( \beta \) | Std. Error | df | \( p \) | 95% Confidence Interval |
|--------------------|-----------|-------------|------------|----|------|------------------------|
|                    |           |             |            |    |      | Lower Bound | Upper Bound |
| Pain intensity     | Intercept | 3.419       | 1.278      | 81.999 | 0.009 | 0.877 | 5.961 |
|                    | Age       | -0.002      | 0.014      | 69.288 | 0.896 | -0.029 | 0.026 |
|                    | Gender    | 1.413       | 0.410      | 65.916 | 0.001 | 0.594 | 2.231 |
|                    | BMI       | 0.007       | 0.011      | 52.907 | 0.528 | -0.015 | 0.030 |
|                    | Depression a | 0.167       | 0.047      | 96.990 | 0.001 | 0.074 | 0.259 |
|                    | Anxiety b  | -0.035      | 0.051      | 94.535 | 0.490 | -0.136 | 0.066 |
|                    | Medicines | 1.242       | 0.751      | 73.503 | 0.102 | -0.253 | 2.738 |
|                    | Inflammation c | 0.453       | 0.890      | 95.329 | 0.612 | -1.314 | 2.219 |
|                    | Time d    | 0.466       | 1.044      | 50.772 | 0.659 | -1.632 | 2.560 |
| PIPS               | Intercept | 35.500      | 7.646      | 79.841 | 0.000 | 20.284 | 50.717 |
|                    | Age       | -0.070      | 0.078      | 63.655 | 0.376 | -0.226 | 0.086 |
|                    | Gender    | 0.837       | 2.466      | 67.533 | 0.735 | -4.085 | 5.759 |
|                    | BMI       | -0.048      | 0.061      | 43.268 | 0.439 | -0.171 | 0.075 |
|                    | Depression a | 1.141       | 0.301      | 97.853 | 0.000 | 0.543 | 1.738 |
|                    | Anxiety b  | 0.370       | 0.301      | 92.076 | 0.223 | -0.229 | 0.968 |
Table 4. Cont.

| Dependent Variable | Parameter | β      | Std. Error | df | p     | Lower Bound | Upper Bound |
|--------------------|-----------|--------|------------|----|-------|-------------|-------------|
| Pain intensity     | −0.545    | 0.605  | 92.909     | 0.370 | −1.746 | 0.657       |
| Medicines          | 8.458     | 4.325  | 68.297     | 0.055 | −0.172 | 17.087      |
| Inflammation       | 3.728     | 5.326  | 97.158     | 0.486 | −6.843 | 14.299      |
| Time               | −19.206   | 6.990  | 52.502     | 0.008 | −33.230 | −5.183      |
| Inflammation + Time| 14.624    | 7.080  | 50.630     | 0.044 | 0.409  | 28.840      |

Dependent variable: Pain Interference Index (PII); Pain intensity; Psychological Inflexibility in Pain Scale (PIPS). 

\( a \) Depression (PHQ-9; Patient Health Questionnaire-9); \( b \) Anxiety (GAD-7; Generalized Anxiety Disorder 7-item scale); \( c \) Mean combined baseline values of TNF-\( \alpha \) and IL-6, log transformed; \( d \) Corresponds to the treatment effect.

Figure 1. Relationship between changes in psychological inflexibility and cytokine levels at baseline.

3. Results

3.1. Participant Characteristics, Procedure and Missing Data

In total, 78 persons (56 women) with chronic pain were included in the analyses, from a total of 89 included in the study. Of these 78, 56 received internet-based treatment (iACT) and 22 received face-to-face treatment. A total of 50% of the participants who received treatment face-to-face had group sessions. At baseline, participants completed questionnaires and donated blood with a mean of 2.5 days (SD 2.9) before treatment and 1.9 days (SD 2.8) after the end of treatment. One participant was excluded as another treatment was indicated, and one due to extreme values in blood cytokines related to another treatment. Nine participants filled in questionnaires with more than 14 days difference in blood sampling and were therefore excluded from the analysis. Fifty-seven of the 78 included participants completed the treatment, resulting in an attrition rate of 25%. Of these, 52 donated blood both before and after treatment.

Due to logistic difficulties in the clinical setting, PHQ-9 and GAD-7 for the first six patients are missing. Descriptive statistics pertaining to demographic and clinical background variables are presented in Table 1 and Supplementary Table S1, and observed mean values and their respective standard deviations for all included self-reported questionnaires across assessments are presented in Table 2. Visual inspection of the plotted residuals from the model and the plotted model residuals against the model predicted values indicated that assumptions of normality were adequately met for analyses with LMM.

3.2. Treatment-Related Effects

As hypothesized, Pain interference (PII) \((β = −4.729, p < 0.001)\) and psychological inflexibility (PIPS) \((β = −7.166, p < 0.001)\) improved significantly during treatment (Table 3). However, pain intensity \((p = 0.078)\) and levels of IL-6 \((p = 0.086)\) and TNF-\( \alpha \) \((p = 0.672)\) did not decrease over time.
3.3. Effect of Inflammation on Treatment Outcomes

Inflammatory levels did not moderate changes in pain interference \( (p = 0.205) \) or pain intensity \( (p = 0.536) \) (Table 4). Mean levels of pro-inflammatory levels did, however, moderate changes in psychological inflexibility \( \beta = 14.624, p = 0.044 \) during treatment (Table 4). Our results indicate that higher mean baseline levels of IL-6 and TNF-\( \alpha \) were related to higher levels of psychological inflexibility during the course of treatment (see Table 4 and Figure 1). This means that patients with lower inflammatory levels showed a greater decrease in psychological inflexibility during ACT treatment as compared to patients with higher inflammatory levels. Sensitivity analyses including only completers yielded a significant relationship between baseline inflammation and changes in PIPS as well, suggesting that this finding is robust.

4. Discussion

Several studies have evaluated the inflammatory profile of patients with pain conditions, e.g., [5,7,8,29], and the effects of behavioral treatment on levels of inflammation [30], but few studies have evaluated the effect of inflammation on behavioral treatment for pain [25,29]. Rather than investigating the efficacy of ACT, which has been studied previously by our group [12,13,31,39–42], the purpose of this study was to understand the potential contribution of baseline low-grade inflammation on the effect of behavioral treatment in patients suffering from chronic pain, assuming ongoing inflammation as one potential variable involved in the large individual variation in treatment efficacy in these patients [9,10].

Results tentatively illustrate that levels of systemic low-grade inflammation moderated the effect of treatment on psychological inflexibility following ACT for chronic pain. These findings are in line with two previous studies, supporting the validity of the findings. Results suggest that baseline inflammation levels can interfere with the effect of treatment on central treatment targets, such as psychological inflexibility. In contrast to our previous study, no moderating effect of inflammation on pain intensity could be seen, nor could we demonstrate a decrease in inflammatory activity due to the treatment. Psychological inflexibility was related to inflammatory levels in the previous study [25], and we investigated pain interference as an outcome variable in this study, as pain interference has been shown to be related to changes in psychological inflexibility in previous research [12]. However, inflammation did not significantly moderate changes in pain interference. The pattern found, of PII and PIPS improving significantly over time during ACT while pain intensity did not, is in line with the previous studies on treatment effects published by our group [12,13,31,39–42]. Here, the focus is on a biological factor that may affect treatment efficacy.

Our study implies a relationship between inflammatory activity and psychological inflexibility as measured with PIPS. As for the biological mechanisms underlying this finding, we consider the demonstrated effects of inflammation on potential experimental analogues to psychological flexibility. Two behavioral mechanisms that have been discussed in previous research and that may have some bearing on this clinical variable are cognitive/mental flexibility and avoidance behaviors [43]. Cognitive or mental flexibility is often defined as the ability to change behaviors, such as thoughts and actions, in response to situational challenges [43]. It is considered to be an executive function, and may be assessed by, e.g., the Intra/Extra-Dimensional (IED) set shift test [44,45] and the Trail Making Test (TMT) [46,47]. Lasselin et al. showed that in obese individuals, a population often showing ongoing low-grade inflammation, subjects with levels of C-reactive protein (CRP) above 5 mg/L performed worse on the IED test compared to obese subjects with lower levels of CRP or non-obese participants [48]. Furthermore, CRP blood levels have been associated with reduced performance in the TMT in several patient groups experiencing ongoing peripheral inflammatory activity, such as those with peripheral arterial disease [49] and brain cancer [50] and aging populations [51]. Blood cytokine levels also affect motivational aspects in experimental models. Although these interactions are complex [52–54], inflammation tends
to reduce approach motivation and enhances avoidance motivation [55]. Aversion models in rodents are perhaps the closest pre-clinical approximation to avoidance behaviors [56], although limitations regarding clinical validity need to be kept in mind when interpreting results. Avoidant behavior in relation to inflammation has been studied extensively in rodents, and distinct immune system-to-brain pathways governing this behavior have been identified. For example, Engblom et al. performed a series of inflammation-induced aversion experiments in rodents that identified interferon-gamma [57] and prostaglandin [58] signaling in the endothelium surrounding the blood vessels in the brain as essential for developing aversive behaviors during induced inflammation. Furthermore, stress-induced monocyte recruitment to the brain resulted in anxiety and social avoidance in wild-type mice. In IL-6 knockout mice, avoidance behaviors were prevented despite maintained immune cell recruitment [59]. The concept of avoidance overlaps conceptually with psychological inflexibility [43]. Thus, the present study adds to the growing body of studies exploring the neurobiological mechanisms, pathophysiological consequences and motivational aspects of approach/avoidance behaviors in relation to inflammatory processes. It should be pointed out that the current analyses are based on inflammatory activity, as this follows prior work and hypotheses. Other biological mechanisms that affect behavior, such as the endogenous opioid system, may have effects that go undetected [60,61].

The current study has both strengths and limitations. A major limitation is the lack of a randomized controlled design, which was also connected to clinical logistics. The lack of a control group makes it difficult to assess if the association would be seen in non-treated groups as a spontaneous occurrence over time and/or if this association is present in non-pain cohorts or healthy controls. We can also not draw conclusions about the cytokine levels of this cohort compared to healthy individuals. Furthermore, we cannot assess the effect of the experimental tests such as blood draw and survey completion. Strengths are that the timing and handling of blood samples were sufficiently standardized, and the Olink analysis panel was shown to have sufficient reproducibility for using single sample analyses. However, the study sample is a group of persons with mixed pain diagnoses, and the diagnosis of the primary condition causing pain was not available. This adds some uncertainty to the interpretation of the results, although not undermining the ecological validity, as it represents the majority of chronic pain patients presenting at most pain clinics. There is also variability in the treatment format. Sensitivity analyses show that the type of treatment did not change the main findings. We chose to include both completers and dropouts in the model, as the LMM can account for missing data, and it should be noted that the main finding of this study remains when only completers were analyzed as well, which suggests that the findings are robust. The study adds to the accumulation of knowledge regarding why treatment effects following behavioral interventions differ across individuals. This knowledge may potentially be used to personalize behavioral treatment, e.g., with regard to duration or content of treatment for certain subgroups, such as patients with higher levels of inflammatory mediators.

5. Conclusions

Following ACT for chronic pain, low-grade baseline inflammation tentatively moderated the effect of treatment on psychological inflexibility but not pain intensity or pain interference. The results from the present study are consistent with prior research linking ongoing inflammatory activity to psychological inflexibility. More information on inflammatory biomarkers may improve the understanding of the variability in treatment outcome and the ability to identify relevant subgroups of patients who may require adapted treatment approaches. These are important steps toward individualizing interventions and potentially improving the effects of these treatment approaches.

Supplementary Materials: The following supporting information can be downloaded at: https://www.mdpi.com/article/10.3390/jcm11092285/s1, Table S1. Additional clinical background variables for all included participants.
Author Contributions: All authors participated in the conceptualization of the study. B.K., R.K.W. L.H. and M.L. designed the study, and provided funding and logistic support. J.Å. and B.K. collected the data. J.Å. and B.K. carried out the descriptive analyses. B.K. and M.K.K. carried out the inferential analyses with contribution from J.Å. B.K. wrote the first draft of the manuscript, and all authors interpreted the results and contributed to the final draft. All authors have read and agreed to the published version of the manuscript.

Funding: We thank the following for financial support: Swedish Research Council (BK) (Grant number 2017-00489), Swedish Society of Medicine (BK) (Grant number SLS-691251), Sweden-America Foundation (BK), Fulbright Sweden (BK), Heart-Lung Foundation (BK) (Grant number 20190110), AFA Insurance (R.K.W., J.Å.) (Grant number 140350), Stockholm County Council ALF (J.Å.), and Medical Unit Medical Psychology at the Karolinska University Hospital (J.Å.).

Institutional Review Board Statement: The study was conducted in accordance with the Declaration of Helsinki, and approved by the Regional Ethical Review Board in Stockholm, Sweden (Permit Number: 2016/1252-31/2). The study is registered at ClinicalTrials.gov, Reg no. NCT03272893 [https://clinicaltrials.gov/ct2/show/NCT03272893] (accessed on 7 March 2022).

Informed Consent Statement: Informed consent was obtained from all subjects involved in the study.

Data Availability Statement: Data available upon request, please contact the main author.

Acknowledgments: We are grateful to the participants for their contribution, and we thank colleagues at Behavioral Medicine, Karolinska Hospital, Sweden, for help with data collection. We are also grateful for the support we have received in form of research grants to pursue this research question.

Conflicts of Interest: The authors declare no conflict of interest.

References
1. Breivik, H.; Collett, B.; Ventafridda, V.; Cohen, R.; Gallacher, D. Survey of chronic pain in Europe: Prevalence, impact on daily life, and treatment. Eur. J. Pain 2006, 10, 287–333. [CrossRef] [PubMed]
2. Interagency Pain Research Coordinating Committee. National Pain Strategy: A Comprehensive Population Health-Level Strategy for Pain; National Institutes of Health: Bethesda, MD, USA, 2016.
3. Treede, R.D.; Rief, W.; Barke, A.; Aziz, Q.; Bennett, M.I.; Benoliel, R.; Cohen, M.; Evers, S.; Finnerup, N.B.; First, M.B.; et al. Chronic pain as a symptom or a disease: The IASP Classification of Chronic Pain for the International Classification of Diseases (ICD-11). Pain 2019, 160, 19–27. [CrossRef] [PubMed]
4. Von Korff, M.; Scher, A.I.; Helmick, C.; Carter-Pokras, O.; Dodick, D.W.; Goulet, J.; Hamill-Ruth, R.; LeResche, L.; Porter, L.; Tait, R.; et al. United States National Pain Strategy for Population Research: Concepts, Definitions, and Pilot Data. J. Pain 2016, 17, 1068–1080. [CrossRef]
5. DeVon, H.A.; Piano, M.R.; Rosenfeld, A.G.; Hoppensteadt, D.A. The association of pain with protein inflammatory biomarkers: A review of the literature. Nurs. Res. 2014, 63, 51–62. [CrossRef]
6. Andres-Rodriguez, L.; Borras, X.; Feliu-Soler, A.; Perez-Aranda, A.; Angarita-Osorio, N.; Moreno-Peral, P.; Montero-Marin, J.; Garcia-Campayo, J.; Carvalho, A.F.; Maes, M.; et al. Peripheral immune aberrations in fibromyalgia: A systematic review, meta-analysis and meta-regression. Brain Behav. Immun. 2020, 87, 881–889. [CrossRef] [PubMed]
7. Hung, A.L.; Lim, M.; Doshi, T.L. Targeting cytokines for treatment of neuropathic pain. Scand. J. Pain 2017, 17, 287–293. [CrossRef]
8. Khan, A.N.; Jacobsen, H.E.; Khan, J.; Filippi, C.G.; Levine, M.; Lehman, R.A., Jr.; Riew, K.D.; Lenke, L.G.; Chahine, N.O. Inflammatory biomarkers of low back pain and disc degeneration: A review. Ann. N. Y. Acad. Sci. 2017, 1410, 68–84. [CrossRef]
9. Williams, A.C.C.; Fisher, E.; Hearn, L.; Eccleston, C. Psychological therapies for the management of chronic pain (excluding headache) in adults. Cochrane Database Syst. Rev. 2020, 8, CD007407. [CrossRef]
10. Vlaeyen, J.W.; Morley, S. Cognitive-behavioral treatments for chronic pain: What works for whom? Clin. J. Pain 2005, 21, 1–8. [CrossRef]
11. Hayes, S.C.; Luoma, J.B.; Bond, F.W.; Masuda, A.; Lillis, J. Acceptance and commitment therapy: Model, processes and outcomes. Behav. Res. Ther. 2006, 44, 1–25. [CrossRef]
12. Kemani, M.K.; Hesser, H.; Olsson, G.L.; Lekander, M.; Wicksell, R.K. Processes of change in Acceptance and Commitment Therapy and Applied Relaxation for long-standing pain. Eur. J. Pain 2016, 20, 521–531. [CrossRef] [PubMed]
13. Gentili, C.; Rickardsson, J.; Zetterqvist, V.; Simons, L.E.; Lekander, M.; Wicksell, R.K. Psychological Flexibility as a Resilience Factor in Individuals With Chronic Pain. Front. Psychol. 2019, 10, 2016. [CrossRef] [PubMed]
14. Wicksell, R.K.; Lekander, M.; Sorjonen, K.; Olsson, G.L. The Psychological Inflexibility in Pain Scale (PIPS)—Statistical properties and model fit of an instrument to assess change processes in pain related disability. Eur. J. Pain 2010, 14, 771.e1–771.e14. [CrossRef] [PubMed]
15. Wicksell, R.K.; Olsson, G.L.; Hayes, S.C. Psychological flexibility as a mediator of improvement in Acceptance and Commitment Therapy for patients with chronic pain following whiplash. Eur. J. Pain 2010, 14, 1059.e1–1059.e11. [CrossRef]

16. McCracken, L.M.; Vowles, K.E. Psychological Flexibility and traditional pain management strategies in relation to patient functioning with chronic pain: An examination of a revised instrument. J. Pain 2007, 8, 700–707. [CrossRef] [PubMed]

17. Zetterqvist, V.; Holmstrom, L.; Maathz, P.; Wicksell, R.K. Pain avoidance predicts disability and depressive symptoms three years later in individuals with whiplash complaints. Acta Anaesthesiol. Scand. 2017, 61, 445–455. [CrossRef] [PubMed]

18. Kemani, M.K.; Zetterqvist, V.; Kanstrup, M.; Holmstrom, L.; Wicksell, R.K. A validation of the pain interference index in adults with long-standing pain. Acta Anaesthesiol. Scand. 2016, 60, 250–258. [CrossRef]

19. Kemani, M.K.; Olsson, G.L.; Lekander, M.; Hesser, H.; Andersson, E.; Wicksell, R.K. Efficacy and Cost-effectiveness of Acceptance and Commitment Therapy and Applied Relaxation for Longstanding Pain: A Randomized Controlled Trial. Clin. J. Pain 2015, 31, 1004–1016. [CrossRef]

20. Karshikoff, B.; Tadros, M.A.; Mackey, S.; Zouikr, I. Neuroimmune modulation of pain across the developmental spectrum. Curr. Opin. Behav. Sci. 2019, 28, 85–92. [CrossRef]

21. Kraynak, T.E.; Marsland, A.L.; Wager, T.D.; Gianaras, P.J. Functional neuroanatomy of peripheral inflammatory physiology: A meta-analysis of human neuroimaging studies. Neurosci. Biobehav. Rev. 2018, 94, 76–92. [CrossRef]

22. Lasselin, J.; Lekander, M.; Axelsson, J.; Karshikoff, B. Sex differences in how inflammation affects behavior: What we can learn from experimental inflammatory models in humans. Front. Neuroenergocrinol. 2018, 50, 91–106. [CrossRef] [PubMed]

23. Lasselin, J.; Schedlowski, M.; Karshikoff, B.; Engler, H.; Lekander, M.; Konsman, J.P. Comparison of bacterial lipopolysaccharide-induced sickness behavior in rodents and humans: Relevance for symptoms of anxiety and depression. Neurosci. Biobehav. Rev. 2020, 115, 115–24. [CrossRef] [PubMed]

24. Osimo, E.F.; Pillinger, T.; Rodriguez, I.M.; Khandaker, G.M.; Pariante, C.M.; Howes, O.D. Inflammatory markers in depression: A meta-analysis of mean differences and variability in 5166 patients and 5083 controls. Brain Behav. Immun. 2020, 87, 901–909. [CrossRef] [PubMed]

25. Lasselin, J.; Kemani, M.K.; Kanstrup, M.; Olsson, G.L.; Axelsson, J.; Andreasson, A.; Lekander, M.; Wicksell, R.K. Low-grade inflammation may moderate the effect of behavioral treatment for chronic pain in adults. J. Behav. Med. 2016, 39, 916–924. [CrossRef] [PubMed]

26. Carvalho, L.A.; Torre, J.P.; Papadopoulos, A.S.; Poon, L.; Juruena, M.F.; Markopoulou, K.; Cleare, A.J.; Pariante, C.M. Lack of clinical therapeutic benefit of antidepressants is associated overall activation of the inflammatory system. J. Affect. Disorder. 2012, 148, 136–140. [CrossRef] [PubMed]

27. Haroon, E.; Daguanno, A.W.; Woolwine, B.J.; Goldsmith, D.R.; Baer, W.M.; Wommack, E.C.; Felger, J.C.; Miller, A.H. Antidepressant treatment resistance is associated with increased inflammatory markers in patients with major depressive disorder. Psychoneuroendocrinology 2018, 95, 43–49. [CrossRef]

28. Jeng, J.S.; Li, C.T.; Chen, M.H.; Lin, W.C.; Bai, Y.M.; Tsai, S.J.; Su, T.P.; Chang, W.H.; Sung, Y.J. Repeated Low-Grade Infections Predict Antidepressant-Resistant Depression: A Nationwide Population-Based Cohort Study. J. Clin. Psychiatry 2018, 79, 17454. [CrossRef]

29. Andres-Rodriguez, L.; Borras, X.; Feliu-Soler, A.; Perez-Aranda, A.; Rozadilla-Sacanell, A.; Montero-Marin, J.; Maes, M.; Luciano, J.V. Immune-inflammatory pathways and clinical changes in fibromyalgia patients treated with Mindfulness-Based Stress Reduction (MBSR): A randomized, controlled clinical trial. Brain Behav. Immun. 2019, 80, 109–119. [CrossRef]

30. O’Toole, M.S.; Bovbjerg, D.H.; Renna, M.E.; Lekander, M.; Mennin, D.S.; Zachariae, R. Effects of psychological interventions on systemic levels of inflammatory biomarkers in humans: A systematic review and meta-analysis. Brain Behav. Immun. 2018, 74, 68–78. [CrossRef]

31. Rickardsson, J.; Gentili, C.; Holmstrom, L.; Zetterqvist, V.; Andersson, E.; Persson, J.; Lekander, M.; Ljotsson, B.; Wicksell, R.K. Internet-delivered acceptance and commitment therapy as microlearning for chronic pain: A randomized controlled trial with 1-year follow-up. Eur. J. Pain 2021, 25, 1012–1030. [CrossRef]

32. Wicksell, R.K.; Renofalt, J.; Olsson, G.L.; Bond, F.W.; Melin, L. Avoidance and cognitive fusion–central components in pain related disability? Development and preliminary validation of the Psychological Inflexibility in Pain Scale (PIPS). Eur. J. Pain 2008, 12, 491–500. [CrossRef] [PubMed]

33. Spitzer, R.L.; Kroenke, K.; Williams, J.B.; Lowe, B. A brief measure for assessing generalized anxiety disorder: The GAD-7. Arch. Intern. Med. 2006, 166, 1092–1097. [CrossRef] [PubMed]

34. Kroenke, K.; Spitzer, R.L.; Williams, J.B.W. The PHQ-9—Validity of a brief depression severity measure. J. Gen. Intern. Med. 2001, 16, 606–613. [CrossRef] [PubMed]

35. Shafer, J.L.; Graham, J.W. Missing data: Our view of the state of the art. Psychol. Methods 2002, 7, 147–177. [CrossRef] [PubMed]

36. Burnham, K.P.; Anderson, D.R. Multimodel Inference: Understanding AIC and BIC in Model Selection. Sociol. Methods Res. 2004, 33, 261–304. [CrossRef]

37. R Core Team. R: A Language and Environment for Statistical Computing; R Foundation for Statistical Computing: Vienna, Austria, 2019; Available online: https://www.R-project.org/ (accessed on 10 November 2021).

38. Yoshida, K. Tableone: Create “Table 1” to Describe Baseline Characteristics. R Package Version 0.10.0. 2019. Available online: https://cran.r-project.org/package=tableone (accessed on 10 November 2021).
39. Gentili, C.; Zetterqvist, V.; Rickardsson, J.; Holmstrom, L.; Simons, L.E.; Wicksell, R.K. ACTsmart—Development and feasibility of digital Acceptance and Commitment Therapy for adults with chronic pain. NPJ Digit. Med. 2020, 3, 20. [CrossRef] [PubMed]

40. Gentili, C.; Zetterqvist, V.; Rickardsson, J.; Holmstrom, L.; Simons, L.E.; Wicksell, R.K. ACTsmart: Guided Smartphone-Delivered Acceptance and Commitment Therapy for Chronic Pain-A Pilot Trial. Pain Med 2020, 22, 315–328. [CrossRef]

41. Holmberg, J.; Kemani, M.K.; Holmstrom, L.; Ost, L.G.; Wicksell, R.K. Psychological Flexibility and Its Relationship to Distress and Work Engagement Among Intensive Care Medical Staff. Front. Psychol. 2020, 11, 603986. [CrossRef]

42. Rickardsson, J.; Zetterqvist, V.; Gentili, C.; Andersson, E.; Holmstrom, L.; Lekander, M.; Persson, M.; Persson, J.; Ljotsson, B.; Wicksell, R.K. Internet-delivered acceptance and commitment therapy (iACT) for chronic pain-feasibility and preliminary effects in clinical and self-referred patients. Mhealth 2020, 6, 27. [CrossRef]

43. Whiting, D.L.; Deane, F.P.; Simpson, G.K.; McLeod, H.J.; Ciarrochi, J. Cognitive and psychological flexibility after a traumatic brain injury and the implications for treatment based on acceptance and commitment therapy: A conceptual review. Neuropsychol. Rehabil. 2017, 27, 263–299. [CrossRef]

44. Robbins, T.W.; James, M.; Owen, A.M.; Sahakian, B.J.; McNInnes, L.; Rabbitt, P. Cambridge Neuropsychological Test Automated Battery (CANTAB): A factor analytic study of a large sample of normal elderly volunteers. Dementia 1994, 5, 266–281. [CrossRef] [PubMed]

45. Sahakian, B.J.; Owen, A.M. Computerized assessment in neuropsychiatry using CANTAB: Discussion paper. J. R. Soc. Med. 1992, 85, 399–402. [PubMed]

46. Corrigan, J.D.; Hinkeldey, N.S. Relationships between parts A and B of the Trail Making Test. J. Clin. Psychol. 1987, 43, 402–409. [CrossRef]

47. Gaudino, E.A.; Geisler, M.W.; Squires, N.K. Construct validity in the Trail Making Test: What makes Part B harder? Neuropsychol. 1995, 17, 529–535. [CrossRef] [PubMed]

48. Lasselin, J.; Magne, E.; Beau, C.; Aubert, A.; Dexpert, S.; Carrez, J.; Laye, S.; Forestier, D.; Ledaguenel, P.; Capuron, L. Low-grade inflammation is a major contributor of impaired attentional set shifting in obese subjects. Brain Behav. Immun. 2016, 58, 63–68. [CrossRef] [PubMed]

49. Mangiafico, R.A.; Sarnatato, F.; Mangiafico, M.; Fiore, C.E. Impaired cognitive performance in asymptomatic peripheral arterial disease: Relation to C-reactive protein and D-dimer levels. Age Ageing 2006, 35, 60–65. [CrossRef]

50. Parkevici, A.; Deltuva, V.P.; Tamasauskas, A.; Zegliene, J.; Bunevicius, A. Clinical and Biological Correlates of Preoperative Cognitive Functioning of Glioma and Meningioma Patients. BioMed Res. Int. 2020, 2020, 2054859. [CrossRef]

51. Marioni, R.E.; Stewart, M.C.; Murray, G.D.; Deary, I.J.; Fowkes, F.G.; Lowe, G.D.; Rumley, A.; Price, J.F. Peripheral levels of fibrinogen, C-reactive protein, and plasma viscosity predict future cognitive decline in individuals without dementia. Psychosom. Med. 2009, 71, 901–906. [CrossRef] [PubMed]

52. Lasselin, J.; Treadway, M.T.; Lacourt, T.E.; Soop, A.; Olsson, M.J.; Karshikoff, B.; Pauess-Goranson, S.; Axelsson, J.; Dantzer, R.; Lekander, M. Lipopolysaccharide Alters Motivated Behavior in a Monetary Reward Task: A Randomized Trial. Neuropsychopharmacol. Off. Publ. Am. Coll. Neuropsychopharmacol. 2017, 42, 801–810. [CrossRef]

53. Vichaya, E.G.; Hunt, S.C.; Dantzer, R. Lipopolysaccharide reduces incentive motivation while boosting preference for high reward in mice. Neuropsychopharmacol. Off. Publ. Am. Coll. Neuropsychopharmacol. 2014, 39, 2884–2890. [CrossRef]

54. Vichaya, E.G.; Laumet, G.; Christian, D.L.; Grossberg, A.J.; Estrada, D.J.; Heijnen, C.J.; Kavelaars, A.; Robert, D. Motivational changes that develop in a mouse model of inflammation-induced depression are independent of indoleamine 2,3 dioxygenase. Neuropsychopharmacol. Off. Publ. Am. Coll. Neuropsychopharmacol. 2018, 44, 364–371. [CrossRef] [PubMed]

55. Vichaya, E.G.; Dantzer, R. Inflammation-induced motivational changes: Perspective gained by evaluating positive and negative valence systems. Curr. Opin. Behav. Sci. 2018, 22, 90–95. [CrossRef] [PubMed]

56. Mkrtschian, A.; Aylward, J.; Dayan, P.; Roiser, J.P.; Robinson, O.J. Modeling Avoidance in Mood and Anxiety Disorders Using Reinforcement Learning. Biol. Psychiatry 2017, 82, 532–539. [CrossRef] [PubMed]

57. Fritz, M.; Klawonn, A.M.; Jaarola, M.; Engblom, D. Interferon-γ mediated signaling in the brain endothelium is critical for inflammation-induced aversion. Brain Behav. Immun. 2018, 54, 57–58. [CrossRef] [PubMed]

58. Fritz, M.; Klawonn, A.M.; Nilsson, A.; Singh, A.K.; Zajdel, J.; Wilhelms, D.B.; Lazarus, M.; Lofberg, A.; Jaarola, M.; Kugelberg, U.O.; et al. Prostaglandin-dependent modulation of dopaminergic neurotransmission elicits inflammation-induced aversion in mice. J. Clin. Invest. 2016, 126, 695–705. [CrossRef]

59. Niraulla, A.; Witcher, K.G.; Sheridan, J.F.; Godbout, J.P. Interleukin-6 Induced by Social Stress Promotes a Unique Transcriptional Signature in the Monocytes That Facilitate Anxiety. Biol. Psychiatry 2019, 85, 679–689. [CrossRef]

60. Kabadi, R.; Kouya, F.; Cohen, H.W.; Banik, R.K. Spontaneous pain-like behaviors are more sensitive to morphine and buprenorphine than mechanically evoked behaviors in a rat model of acute postoperative pain. Anesth. Analg. 2015, 120, 472–478. [CrossRef]

61. Paul, A.K.; Gueven, N.; Dietis, N. Profiling the Effects of Repetitive Morphine Administration on Motor Behavior in Rats. Molecules 2021, 26, 4355. [CrossRef]